CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today results from 32 studies on the INTERCEPT Blood System presented at the International Congress of the International Society of Blood Transfusion in Macao SAR, China. Study outcomes highlight clinical experience implementing the INTERCEPT Blood System for platelets and plasma into routine practice. Others demonstrate INTERCEPT’s utility in the inactivation of current and emerging pathogens, such as malaria and avian influenza, in donated blood. The safety and efficacy of the INTERCEPT Blood System are also highlighted in results from a multi-year hemovigilence surveillance program and in a study of patients with a severe congenital bleeding disorder undergoing major surgery.
